ArticleACS omega2023
Performance Enhancement of an MoS
Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Multiscale quantum-to-device simulation framework for CaScientific reports · 2026Article
- Robust Material Properties in Epitaxial InSmall (Weinheim an der Bergstrasse, Germany) · 2025Article
- Performance evaluation of EuRSC advances · 2025Article
- First-principles investigation and photovoltaic assessment of CsRSC advances · 2025Article
- Performance evaluation of CuScientific reports · 2025Article
- Optimizing solar performance of CFTSe-based solar cells using MoSeScientific reports · 2025Article
- A comprehensive study on electron and hole transport layers for designing and optimizing the efficiency of MoSeHeliyon · 2024Article
- Design and Optimization of High-Performance Novel RbPbBrACS omega · 2024Article
- Article
- Emerging BaZrSACS omega · 2024Article
- Improving the efficiency of a CIGS solar cell to above 31% with SbRSC advances · 2024Article
- Article
- Boosting efficiency above 28% using effective charge transport layer with SrRSC advances · 2023Article
- Optimization and Performance Analysis of a TiOACS omega · 2023Article
- Achieving above 24% efficiency with non-toxic CsSnIRSC advances · 2023Article
- Harnessing the potential of CsPbBrRSC advances · 2023Article
- Deep Insights into the Coupled Optoelectronic and Photovoltaic Analysis of Lead-Free CsSnIACS omega · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Researchers are currently showing interest in molybdenum disulfide (MoS
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.